Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Future prospects for oncolytic therapy

Oncogene volume 24, pages 7817–7819 (2005)Cite this article

Abstract

Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology,

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Aghia M and Martuza RL . (2005). Oncogne, x, x–x (this issue).

  • Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu T-J, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WKA and Lang FF . (2003). J. Natl. Cancer Inst., 95, 652–660.

  • Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L and Kirn D . (2000). Nat. Med., 6, 1134–1139.

  • Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F and Fattaey A . (2002). Cancer Cell, 1, 325–337.

  • Ko D, Hawkins L and Yu DC . (2005). Oncogene, x, x–x (this issue).

  • McCormick F . (2001). Nat. Rev. Cancer, 1, 130–141.

  • Nemunaitis J and Edelman J . (2002). Cancer Gene Ther., 9, 987–1000.

  • O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Shen Y, Habets G, Ginzinger D and McCormick F . (2004). Cancer Cell, 6, 611–623.

  • Reid T, Warren R and Kirn D . (2002). Cancer Gene Ther., 9, 979–986.

  • Reid T, Galeris E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J and Kirn D . (2001). Gene Therapy, 8, 1618–1626.

  • Yu C, DeWeeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf D, Henderson DR and Yu D-C . (2001). Cancer Res., 61, 5453–5460.

Download references

Author information

Authors and Affiliations

  1. University of California San Francisco, Cancer Research Institute, 94115, 2340 Sutter Street, CA, USA

    Frank McCormick

Authors
  1. Frank McCormick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank McCormick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCormick, F. Future prospects for oncolytic therapy. Oncogene 24, 7817–7819 (2005). https://doi.org/10.1038/sj.onc.1209064

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209064

Keywords

Search

Advanced search

Quick links